Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20166185rdf:typepubmed:Citationlld:pubmed
pubmed-article:20166185lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0042769lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C2698872lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0728831lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0016674lld:lifeskim
pubmed-article:20166185lifeskim:mentionsumls-concept:C0205309lld:lifeskim
pubmed-article:20166185pubmed:issue4lld:pubmed
pubmed-article:20166185pubmed:dateCreated2010-2-26lld:pubmed
pubmed-article:20166185pubmed:abstractTextTo monitor the prevalence of hepatitis B and hepatitis C a cross-sectional survey was conducted in 2004 among French metropolitan residents. A complex sampling design was used to enroll 14,416 adult participants aged 18-80 years. Data collected included demographic and social characteristics and risk factors. Sera were tested for anti-HCV, HCV-RNA, anti-HBc and HBsAg. Data were analyzed with SUDAAN software to provide weighted estimates for the French metropolitan resident population. The overall anti-HCV prevalence was 0.84% (95% CI: 0.65-1.10). Among anti-HCV positive individuals, 57.4% (95% CI: 43.2-70.5) knew their status. Factors associated independently with positive anti-HCV were drug use (intravenous and nasal), blood transfusion before 1992, a history of tattoos, low socioeconomic status, being born in a country where anti-HCV prevalence >2.5%, and age >29 years. The overall anti-HBc prevalence was 7.3% (95%: 6.5-8.2). Independent risk factors for anti-HBc were intravenous drug use, being a man who has sex with men, low socioeconomic status, a stay in a psychiatric facility or facility for the mentally disabled, <12 years of education, being born in a country where HBsAg prevalence >2%, age >29 and male sex. The HCV RNA and HBsAg prevalence were 0.53% (95% CI: 0.40-0.70) and 0.65% (95% CI: 0.45-0.93), respectively. Among HBsAg positive individuals, 44.8% (95% CI: 22.8-69.1) knew their status. Anti-HCV prevalence was close to the 1990s estimates whereas HBsAg prevalence estimate was greater than expected. Screening of hepatitis B and C should be strengthened and should account for social vulnerability.lld:pubmed
pubmed-article:20166185pubmed:languageenglld:pubmed
pubmed-article:20166185pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20166185pubmed:citationSubsetIMlld:pubmed
pubmed-article:20166185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20166185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20166185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20166185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20166185pubmed:statusMEDLINElld:pubmed
pubmed-article:20166185pubmed:monthAprlld:pubmed
pubmed-article:20166185pubmed:issn1096-9071lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:DesenclosJean...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:Delarocque-As...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:MeffreChristi...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:GueguenRenéRlld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:MeyerJean-Fra...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:GiordanellaJe...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:SteinmetzJosi...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:WarszawskiJos...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:AntonaDeniseDlld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:Le StratYannYlld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:DuboisFréderi...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:LemassonJean-...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:CosteDominiqu...lld:pubmed
pubmed-article:20166185pubmed:authorpubmed-author:LeiserSandrin...lld:pubmed
pubmed-article:20166185pubmed:copyrightInfo2010 Wiley-Liss, Inc.lld:pubmed
pubmed-article:20166185pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20166185pubmed:volume82lld:pubmed
pubmed-article:20166185pubmed:ownerNLMlld:pubmed
pubmed-article:20166185pubmed:authorsCompleteYlld:pubmed
pubmed-article:20166185pubmed:pagination546-55lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:meshHeadingpubmed-meshheading:20166185...lld:pubmed
pubmed-article:20166185pubmed:year2010lld:pubmed
pubmed-article:20166185pubmed:articleTitlePrevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.lld:pubmed
pubmed-article:20166185pubmed:affiliationNational Institute for Public Health Surveillance, Saint-Maurice, France.lld:pubmed
pubmed-article:20166185pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20166185pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed